How Much of a Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages

How Much of a Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages

Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide whether to stay on an immunotherapy treatment that was making him very ill. For six months in 2022, Manski received monthly infusions of nivolumab to fight advanced melanoma. The drug ruined his thyroid gland, he said, requiring him to go on a special medication for the rest of his life, and …